Prot #PACT-0101: A Phase 1a/1b, Open Label First-in-Human Study of The Safety, Tolerability and Feasibility of Gene Edited Autologous NeoTCR T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination with Anti-PD-1 to Patients with Locally Advan

Project: Research project

Project Details

Effective start/end date1/28/211/28/24


  • ICON Clinical Research, LLC (Prot #PACT-0101)
  • PACT Pharma, Inc. (Prot #PACT-0101)